ClinicalTrials.gg
CompletedNCT05363215Updated Apr 24, 2023

A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants

A Phase 1 interventional study of S-217622 in Renal Impairment, sponsored by Shionogi. Completed at 4 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-24.

Sponsored by Shionogi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2023, 3 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
216th of 468
32 · median 32
Started
2022
with 25 others
Phase 1
232 of 553
14 open now
Registered
459th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 216th largest by enrollment of the 468 interventional ones that give a count, is one of 26 that started in 2022, is one of 232 in phase 1, and was the 459th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to measure the PK, safety, and tolerability of S-217622 in participants with mild, moderate, or severe renal impairment and in those with normal renal function.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight ≥ 50 kilograms (kg) and (BMI) within the range of ≥ 18.5 to \< 38.0 kilogram-meter squared (kg/m\^2) at the Screening visit

Participants With Renal Impairment

  • Participants that are not undergoing dialysis must have mild, moderate, or severe renal impairment based upon their Modification of Diet in Renal Disease () estimate (estimated glomerular filtration rate [eGFR]) calculated at the Screening visit:

    1. Mild renal impairment: 60 to 89 milliliters per minute (mL/min)/1.73 m\^2
    2. Moderate renal impairment: 30 to 59 mL/min/1.73 m\^2
    3. Severe renal impairment: No lower limit of eGFR, \<30 mL/min
  • A stable medication regimen is required, defined as not starting new drug(s) or changing dosage(s) within 14 days prior to administration of study intervention through the Follow-up/Early Termination visit.

Healthy Participants

  • Participants with clinical laboratory tests within normal reference range for the laboratory, or abnormal but considered not by the investigator. Renal function, calculated by MDRD, must be normal (ie, eGFR > 90 mL/min/1.73 m\^2).
  • Matched to each participant with moderate renal impairment with respect to sex, age (± 5 years), and BMI (± 10%).

Exclusion criteria

Exclusion Criteria:

  • Participants with less than 3 months.
  • History or presence of/significant history of or current cardiovascular, respiratory, hepatic, gastrointestinal (GI), endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • History of GI surgery including but not limited to gastric resection and/or intestinal resection that resulted in a abnormality in GI function.
  • Lymphoma, leukemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years.
  • Breast cancer within the past 10 years.
  • Participant with poor venous access.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    S-217622: Group A

    Participants with mild renal impairment will receive a single dose of S-217622 on Day 1, in a fasted state.

    Drug: S-217622

  • Experimental
    S-217622: Group B

    Participants with moderate renal impairment will receive a single dose of S-217622 on Day 1, in a fasted state.

    Drug: S-217622

  • Experimental
    S-217622: Group C

    Participants with severe renal impairment will receive a single dose of S-217622 on Day 1, in a fasted state.

    Drug: S-217622

  • Experimental
    S-217622: Group D

    Participants with normal renal function will receive a single dose of S-217622 on Day 1, in a fasted state.

    Drug: S-217622

Interventions

  • Tablet for oral administration

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of S-217622

    Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15

  2. Time to Maximum Plasma Concentration (Tmax) of S-217622

    Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15

  3. Area Under the Plasma Concentration-Time Curve (AUC) of S-217622

    Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15

  4. Terminal Elimination Half-Life (t1/2,z) of S-217622

    Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15

  5. Terminal Elimination Rate Constant (λz) of S-217622

    Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15

  6. Mean Residence Time (MRT) of S-217622

    Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15

  7. Apparent Total Clearance (CL/F) of S-217622

    Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15

  8. Apparent Volume of Distribution (Vz/F) of S-217622

    Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15

  9. Renal Clearance (CLR) of S-217622

    Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15

  10. Fraction of Dose Excreted in Urine (Feu) of S-217622

    Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15

  11. Fraction Unbound in Plasma (FU) of S217622

    Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15

Secondary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events

    Time frame: Up to Day 21

07

Study locations

4 sites
  • Clinical Pharmacology of Miami, LLC
    Miami, Florida 33014, United States
  • Advanced Pharma CR, LLC
    Miami, Florida 33147, United States
  • Orlando Clinical Research Center, Inc.
    Orlando, Florida 32809, United States
  • Nucleus Network
    Saint Paul, Minnesota 55114, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Apr 2023, 8 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 8 months is close to that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2022
First posted
May 5, 2022
StartActual
Aug 10, 2022
Primary completionActual
Apr 12, 2023
CompletionActual
Apr 12, 2023
Last update
Apr 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05363215
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
May 5, 2022
Start date
Aug 10, 2022
Primary completion
Apr 12, 2023
Completion
Apr 12, 2023
Last update
Apr 24, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensitrelvir

Start the discussion